Esepapogene zalarnarepvec

N/A

Report date: 2026/04/25 20:00:23

Base Information

Drug NameEsepapogene zalarnarepvec
Drug Alias NameHB-201HB-200 programme
ClassificationVaccines
Mechanisms of ActionProtein E6 modulatorsProtein E7 modulators
TargetsProtein E6Protein E7
Therapy Area/IndicationsUterine Cervical NeoplasmsOropharyngeal NeoplasmsHead and Neck Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsSpain
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesHookipa Biotech Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesHookipa Biotech GmbhThe University Of Chicago
Inactive CompaniesN/A
Active IndicationsOropharyngeal NeoplasmsHead and Neck NeoplasmsCarcinoma, Squamous Cell +[4] 
Inactive IndicationsUterine Cervical Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A